Actively Recruiting
The Prevalence, Risk Factors and Optimal Biopsy Protocol of BE
Led by E-DA Hospital · Updated on 2023-05-11
165
Participants Needed
1
Research Sites
198 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Detections of goblet cells and dysplasia are crucial for diagnosis and determining the surveillance program of Barrett's esophagus (BE). However, the optimal biopsy numbers and their yield rates of intestinal metaplasia (IM) and dysplasia are still uncertain, especially in Asia. The aim of this study was to determine the optimal biopsy protocol of BE.
CONDITIONS
Official Title
The Prevalence, Risk Factors and Optimal Biopsy Protocol of BE
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults with columnar-lined esophagus
You will not qualify if you...
- Prior history of endoscopic treatment for Barrett's Esophagus
- Prior history of upper gastrointestinal cancer
- Prior total or subtotal stomach removal surgery
- Presence of esophageal varices during procedure
- Uncontrolled blood clotting problems
- Currently taking antiplatelet or anticoagulant medications
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
E-DA Hospital
Kaohsiung City, Taiwan, 82445
Actively Recruiting
Research Team
Y
Ying-Nan Tsai, M.D
CONTACT
W
Wen-Lun Wang, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here